In the news

  • Article title

    Q1 'very much a building quarter' for VolitionRx with growing cash reserves

  • Article title

    VolitionRx boosts cash reserves in 1Q, inks distribution deal with Active Motif

  • Article title

    VolitionRx signs distribution agreement with Active Motif to sell research-use-only kits

  • Article title

    VolitionRx bolsters scientific advisory board with Harvard professor

  • Article title

    VolitionRX boss praises “strong progress” in 2017; thinks Nu.QTM panel could be new gold standard in cancer detection

  • Article title

    VolitionRx hails interim results of Danish trial for screening colorectal cancer

  • Article title

    VolitionRx reports positive interim Nu.Q diagnostic results in colorectal cancer

  • Article title

    Cancer Diagnostics group VolitionRX looks ahead to 2018

  • Article title

    VolitionRx eyeing 'breakthrough' 2018 as it completes Copenhagen trial

  • Article title

    The blood trail to diagnose colorectal cancer

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus